The role of complement in the diagnosis and management of allergic rhinitis and allergic asthma

Current Allergy and Asthma Reports

Volumn 11, Issue 2, 2011, Pages 122-130

  Laumonnier, Yves ^a   Schmudde, Inken ^a   Köhl, Jörg ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Allergic asthma; Allergic rhinitis; Complement; Innate immunity; Th17; Th2

Indexed keywords

ANAPHYLATOXIN; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BINDING PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR LIKE 2; CORTICOSTEROID; DECONGESTIVE AGENT; ECULIZUMAB; GLUCOCORTICOID; INTERLEUKIN 17; NGD 1000; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; GENETIC LINKAGE; HUMAN; IMMUNOPATHOGENESIS; MYELOID DENDRITIC CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SENSITIZATION; TH17 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ASTHMA; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C5A; HUMANS; IMMUNITY, CELLULAR; RECEPTORS, COMPLEMENT; RHINITIS; TH17 CELLS; TH2 CELLS;

EID: 79955922349     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-010-0171-6     Document Type: Article

References (69)

1. Bousquet J, Khaltaev N, Cruz AA et al.: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63 Suppl 86: 8-160.
2. Dykewicz MS, Hamilos DL: Rhinitis and sinusitis. J Allergy Clin Immunol 2010, 125: S103-S115.
3. Bateman ED, Hurd SS, Barnes PJ et al.: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31: 143-178.
4. Lambrecht BN, Hammad H: Biology of lung dendritic cells at the origin of asthma. Immunity 2009, 31: 412-424.
5. Al-Ramli W, Prefontaine D, Chouiali F et al.: T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009, 123: 1185-1187.
6. Zhang X, Köhl J: A complex role for complement in allergic asthma. Expert Rev Clin Immunol 2010, 6: 269-277.
7. Köhl J,Wills-Karp M: Complement regulates inhalation tolerance at the dendritic cell/T cell interface. Mol Immunol 2007, 44: 44-56.
8. Köhl J: The role of complement in danger sensing and transmission. Immunol Res 2006, 34: 157-176.
9. Klos A, Tenner AJ, Johswich KO et al.: The role of the anaphylatoxins in health and disease. Mol Immunol 2009, 46: 2753-2766.
10. Bamberg CE, Mackay CR, Lee H et al.: The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010, 285: 7633-7644.
11. Chen NJ, Mirtsos C, Suh D et al.: C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007, 446: 203-207. (Pubitemid 46398661)
12. Rittirsch D, Flierl MA, Nadeau BA et al.: Functional roles for C5a receptors in sepsis. Nat Med 2008, 14: 551-557. (Pubitemid 351655216)
13. Maruo K, Akaike T, Ono T et al.: Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 1997, 100: 253-260. (Pubitemid 27349869)
14. Köhl J, Baelder R, Lewkowich IP et al.: A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 2006, 116: 783-796. (Pubitemid 43326888)
15. Hidvegi T, Schmidt B, Varga L et al.: In vitro complement activation by ragweed allergen extract in the sera of ragweed allergic and non-allergic persons. Immunol Lett 1995, 48: 65-71.
16. Walters DM, Breysse PN, Schofield B, Wills-Karp M: Complement factor 3mediates particulate matter-induced airway hyperresponsiveness. Am J Respir Cell Mol Biol 2002, 27: 413-418.
17. Park JW, Taube C, Joetham A et al.: Complement activation is critical to airway hyperresponsiveness after acute ozone exposure. Am J Respir Crit Care Med 2004, 169: 726-732. (Pubitemid 38338925)
18. Andersson M, Michel L, Llull JB, Pipkorn U: Complement activation on the nasal mucosal surface - a feature of the immediate allergic reaction in the nose. Allergy 1994, 49: 242-245. (Pubitemid 24131449)
19. Mezei G, Varga L, Veres A et al.: Complement activation in the nasal mucosa following nasal ragweed-allergen challenge. Pediatr Allergy Immunol 2001, 12: 201-207. (Pubitemid 32768760)
20. Lane AP, Truong-Tran QA, Myers A et al.: Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue. Am J Rhinol 2006, 20: 117-123.
21. Jun SW, Kim TH, Lee HM et al.: Overexpression of the anaphylatoxin receptors, complement anaphylatoxin 3a receptor and complement anaphylatoxin 5a receptor, in the nasal mucosa of patients with mild and severe persistent allergic rhinitis. J Allergy Clin Immunol 2008, 122: 119-125.
22. Varsano S, Frolkis I, Shapiro H, Ophir D: Human nasal epithelium adsorbs complement C3-related fragments and expresses cell membrane complement regulatory proteins. Laryngoscope 1996, 106: 599-604. (Pubitemid 26137840)
23. Varsano S, Frolkis I, Rashkovsky L et al.: Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Am J Respir Cell Mol Biol 1996, 15: 731-737. (Pubitemid 126441445)
24. Bratke K, Lommatzsch M, Julius P et al.: Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge. Thorax 2007, 62: 168-175.
25. de Heer HJ, Hammad H, Soullie T et al.: Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004, 200: 89-98. (Pubitemid 38924731)
26. Zhang X, Lewkowich IP, Köhl G et al.: A protective role for C5a in the development of allergic asthma associated with altered levels of B7-H1 and B7-DC on plasmacytoid dendritic cells. J Immunol 2009, 182: 5123-5130.
27. KleinJan A, Willart M, van Rijt LS et al.: An essential role for dendritic cells in human and experimental allergic rhinitis. J Allergy Clin Immunol 2006, 118: 1117-1125. (Pubitemid 44666974)
28. Till SJ, Jacobson MR, O'Brien F et al.: Recruitment of CD1a+ Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy. Allergy 2001, 56: 126-131. (Pubitemid 32115762)
29. Lundberg K, Greiff L, Borrebaeck CA, Lindstedt M: FcepsilonRI levels and frequencies of peripheral blood dendritic cell populations in allergic rhinitis. Hum Immunol 2010, 71: 931-933.
30. Nakae S, Komiyama Y, Nambu A et al.: Antigen-specific T cell sensitization is impaired in IL-17-deficientmice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17: 375-387. (Pubitemid 35279557)
31. Schnyder-Candrian S, Togbe D, Couillin I et al.: Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006, 203: 2715-2725. (Pubitemid 44833347)
32. Hellings PW, Kasran A, Liu Z et al.: Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003, 28: 42-50. (Pubitemid 36017049)
33. McKinley L, Alcorn JF, Peterson A et al.: TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008, 181: 4089-4097.
34. Wakashin H, Hirose K, Maezawa Y et al.: IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 2008, 178: 1023-1032.
35. Ciprandi G, De AM, Murdaca G et al.: Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy 2009, 64: 1375-1378.
36. Ciprandi G, Filaci G, Battaglia F, Fenoglio D: Peripheral Th-17 cells in allergic rhinitis: New evidence. Int Immunopharmacol 2010, 10: 226-229.
37. Weaver DJ, Jr., Reis ES, Pandey MK, et al.: C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol 2010, 40: 710-721. This is the first study demonstrating that the lack of C5aR in DCs regulates steadystate Treg formation. Furthermore, it shows that C5aR-deficient DCs favor Th17 cell development when stimulated with a TLR2 ligand in the presence of antigen by an IL-23-dependent mechanism.
38. Lajoie S, Lewkowich IP, Suzuki Y, et al.: Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol 2010, 11: 928-935.
39. Zhang X, Schmudde I, Laumonnier Y et al.: A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol 2010, 185: 6741-6752.
40. Hashimoto M, Hirota K, Yoshitomi H et al.: Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med 2010, 207: 1135-1143.
41. Palomares O, Yaman G, Azkur AK et al.: Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010, 40: 1232-1240.
42. Swarr DT, Hakonarson H: Unraveling the complex genetic underpinnings of asthma and allergic disorders. Curr Opin Allergy Clin Immunol 2010, 10: 434-442.
43. Vercelli D: Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008, 8: 169-182.
44. Davila I, Mullol J, Ferrer M et al.: Genetic aspects of allergic rhinitis. J Investig Allergol Clin Immunol 2009, 19 Suppl 1: 25-31.
45. Suttner K, Depner M, Wetzke M et al.: Genetic variants harbored in the forkhead box protein 3 locus increase hay fever risk. J Allergy Clin Immunol 2010, 125: 1395-1399.
46. Zhang L, Zhang Y, Desrosiers M et al.: Genetic association study of FOXP3 polymorphisms in allergic rhinitis in a Chinese population. Hum Immunol 2009, 70: 930-934.
47. Karp CL, Grupe A, Schadt E et al.: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000, 1: 221-226.
48. Barnes KC, Grant AV, Baltadzhieva D et al.: Variants in the gene encoding C3 are associated with asthma and related phenotypes among African Caribbean families. Genes Immun 2006, 7: 27-35.
49. Hasegawa K, Tamari M, Shao C et al.: Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004, 115: 295-301.
50. Kawai T, Takeshita S, Imoto Yet al.: Associations between decay-accelerating factor polymorphisms and allergic respiratory diseases. Clin Exp Allergy 2009, 39: 1508-1514.
51. Cedzynski M, Atkinson AP, St SA et al.: L-ficolin (ficolin-2) insufficiency is associated with combined allergic and infectious respiratory disease in children. Mol Immunol 2009, 47: 415-419.
52. Dizier MH, Bouzigon E, Guilloud-Bataille M et al.: Genome screen in the French EGEA study: detection of linked regions shared or not shared by allergic rhinitis and asthma. Genes Immun 2005, 6: 95-102. (Pubitemid 40439534)
53. Yokouchi Y, Shibasaki M, Noguchi E et al.: A genome-wide linkage analysis of orchard grass-sensitive childhood seasonal allergic rhinitis in Japanese families. Genes Immun 2002, 3: 9-13. (Pubitemid 38961099)
54. Levy ML, Fletcher M, Price DB et al.: International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J 2006, 15: 20-34. (Pubitemid 43155765)
55. Braunstahl GJ: United airways concept: what does it teach us about systemic inflammation in airways disease? Proc Am Thorac Soc 2009, 6: 652-654.
56. Schlosser RJ, Mulligan RM, Casey SE et al.: Alterations in gene expression of complement components in chronic rhinosinusitis. Am J Rhinol Allergy 2010, 24: 21-25.
57. Humbles AA, Lu B, Nilsson CA et al.: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000, 406: 998-1001.
58. Krug N, Tschernig T, Erpenbeck VJ et al.: Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001, 164: 1841-1843. (Pubitemid 33152317)
59. Nakano Y, Morita S, Kawamoto A et al.: Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003, 112: 525-530. (Pubitemid 37108556)
60. Bowser C, Erstein DP, Silverberg JI, et al.: Correlation of plasma complement split product levels with allergic respiratory disease activity and relation to allergen immunotherapy. Ann Allergy Asthma Immunol 2010, 104: 42-49. This study suggests that determination of plasma C3a and C5a might prove useful to monitor disease activity and the efficacy of asthma therapy.
61. Taube C, Rha YH, Takeda K et al.: Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2003, 168: 1333-1341. (Pubitemid 37487328)
62. Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001, 167: 4141-4145. (Pubitemid 32954285)
63. Peng T, Hao L, Madri JA et al.: Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J Clin Invest 2005, 115: 1590-1600. (Pubitemid 40814667)
64. Bautsch W, Hoymann HG, Zhang Q et al.: Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000, 165: 5401-5405.
65. Drouin SM, Corry DB, Hollman TJ et al.: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002, 169: 5926-5933. (Pubitemid 35291699)
66. Abe M, Shibata K, Akatsu H et al.: Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001, 167: 4651-4660. (Pubitemid 32954346)
67. Baelder R, Fuchs B, Bautsch W et al.: Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005, 174: 783-789. (Pubitemid 40094273)
68. Gail G, Boulet LP, Severino B et al.: The effect of C5 inhibition by eculizumab on allergen-induced asthmatic responses in patients. Mol Immunol 2009, 46: 2837-2838. These are the first preliminary data to indicate that C5 blockade might prove useful as a new therapeutic approach in AA.
69. Fang C, Zhang X, Miwa T, Song WC: Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 2009, 114: 1005-1015.